PT  - JOURNAL ARTICLE
AU  - Grau-Expósito, Judith
AU  - Sánchez-Gaona, Nerea
AU  - Massana, Núria
AU  - Suppi, Marina
AU  - Astorga-Gamaza, Antonio
AU  - Perea, David
AU  - Rosado, Joel
AU  - Falcó, Anna
AU  - Kirkegaard, Cristina
AU  - Torrella, Ariadna
AU  - Planas, Bibiana
AU  - Navarro, Jordi
AU  - Suanzes, Paula
AU  - la Sierra, Daniel Alvarez-de
AU  - Ayora, Alfonso
AU  - Sansano, Irene
AU  - Esperalba, Juliana
AU  - Andrés, Cristina
AU  - Antón, Andrés
AU  - Ramón y Cajal, Santiago
AU  - Almirante, Benito
AU  - Pujol-Borrell, Ricardo
AU  - Falcó, Vicenç
AU  - Burgos, Joaquín
AU  - Buzón, María J.
AU  - Genescà, Meritxell
TI  - Peripheral and lung resident T cell responses against SARS-CoV-2
AID  - 10.1101/2020.12.02.20238907
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.02.20238907
4099  - http://medrxiv.org/content/early/2021/02/05/2020.12.02.20238907.short
4100  - http://medrxiv.org/content/early/2021/02/05/2020.12.02.20238907.full
AB  - Considering that SARS-CoV-2 interacts with the host at the respiratory tract mucosal interface, T cells strategically placed within these surfaces, namely resident memory T cells, will be essential to limit viral spread and disease. Importantly, these cells are mostly non-recirculating, which reduces the window of opportunity to examine circulating lymphocytes in blood as they home to the lung parenchyma. Here, we demonstrate that viral specific T cells can migrate and establish in the lung as resident memory T cells remaining detectable up to 10 months after initial infection. Moreover, focusing on the acute phase of the infection, we identified virus-specific T cell responses in blood with functional, migratory and apoptotic patterns modulated by viral proteins and associated with clinical outcome. Our study highlights IL-10 secretion by virus-specific T cells associated to a better outcome and the persistence of resident memory T cells as key players for future protection against SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThis work was primarily supported by a grant from the Health department of the Government of Catalonia (DGRIS 1_5). This work was additionally supported in part by the Spanish Health Institute Carlos III (ISCIII, PI17/01470 and ISCIII COV20/00416), the Spanish Secretariat of Science and Innovation and FEDER funds (grant RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS network Red Tematica Cooperativa de Investigacion en SIDA (RD16/0025/0007), the European Regional Development Fund (ERDF), the Fundacio La Marato TV3 (grants 201805-10FMTV3 and 201814-10FMTV3) and the Gilead fellowships GLD19/00084 and GLD18/00008. M.J.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). N.M. is supported by a Ph.D. fellowship from the Vall Hebron Institut de Recerca (VHIR) and A.A-G and N.S-G are supported by a Ph.D. fellowship from the Spanish Secretariat of Science and Innovation (BES-2016-076382, PRE2019-087393). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement This study was performed in accordance with the Declaration of Helsinki and approved by the corresponding Institutional Review Board (PR(AG)192/2020 and PR(AG)212/2020) of the Vall Hebron University Hospital (HUVH), Barcelona, Spain. Written informed consent was provided by all patients recruited to this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included as figures and supplementary data.